Contineum Therapeutics, INC Form 4 insider transactions
NASDAQ
Director Troy A. Ignelzi reports the acquisition of stock options in Contineum Therapeutics, Inc.
NASDAQ
Form 4: Versant Venture Capital Entities Report Ownership Changes in Contineum Therapeutics Following IPO
Versant Venture Capital and related entities report the conversion of preferred stock into Class A and Class B common stock of Contineum Therapeutics following the company's initial public offering.